Cervical cancer screening is undergoing a significant shift, offering more options and greater accessibility for individuals with a cervix. At the finish of 2025, the American Cancer Society (ACS) released updated guidelines, and in January 2026, the Health Resources and Services Administration (HRSA) endorsed a similar set of recommendations. These changes center around the increasing use of HPV primary testing and, crucially, the acceptance of self-collected HPV tests, potentially removing barriers to crucial preventative care. Understanding these updated guidelines for HPV screening is vital for anyone seeking to proactively manage their health.
For decades, the Pap test has been the cornerstone of cervical cancer screening, looking for precancerous changes in cells. However, the focus is now shifting towards identifying the root cause of most cervical cancers: the human papillomavirus, or HPV. Both the ACS and HRSA now recommend HPV primary testing as the preferred method for individuals aged 30-65. This test specifically looks for high-risk types of HPV that are known to cause approximately 70% of cervical cancers. If HPV primary testing isn’t available, co-testing – combining an HPV test with a Pap test – is recommended. If neither of those options are available, a Pap test alone remains an acceptable alternative.
Expanding Access with Self-Collection
Perhaps the most impactful change in these recent guidelines is the endorsement of self-collected HPV tests. Traditionally, cervical cancer screening required a pelvic exam and sample collection by a healthcare provider. This can be a significant barrier for many, due to discomfort, lack of access to care, or cultural sensitivities. Recognizing this, both the ACS and HRSA now acknowledge that self-collected HPV tests are a valid option. The ACS prefers provider-collected samples but explicitly states that self-collection is acceptable when provider collection is tough or inaccessible. HRSA similarly supports screening with self-collection as a viable method.
Navigating Follow-Up and Screening Intervals
The frequency of screening depends on the type of test used and the results obtained. For those receiving HPV primary testing or co-testing with provider-collected samples and normal results, a repeat screening is recommended in five years. However, the ACS adds a nuance for those utilizing self-collected HPV tests: individuals with normal results should be screened again in three years. This distinction is not included in the HRSA guidelines. If only a Pap test is performed and results are normal, rescreening is recommended in three years. It’s important to remember that abnormal results will likely necessitate more frequent monitoring.
When Can Screening End?
Both organizations agree that screening can generally end at age 65, provided previous test results have been consistently normal. The ACS is more specific, stating that screening can stop at 65 if there has been a decade of normal results – either negative HPV tests at ages 60 and 65, or three consecutive negative Pap tests, with the last one at age 65. HRSA’s guidelines are less prescriptive regarding past results, simply recommending cessation at age 65.
Differences in Starting Age for Screening
A key difference between the ACS and HRSA guidelines lies in the recommended starting age for screening. The ACS suggests initiating screening at age 25, citing the rarity of cervical cancer in younger individuals. HRSA, however, recommends Pap tests every three years between the ages of 21 and 29, transitioning to HPV primary testing or co-testing at age 30. This difference reflects ongoing discussions about the optimal balance between early detection and the potential for overdiagnosis and overtreatment in younger populations.
What This Means for Patients and Insurance Coverage
For most individuals, the specific screening test offered will depend on their healthcare provider’s practice. However, the growing preference for HPV primary testing suggests a likely shift in the coming years. Importantly, HRSA’s guidelines carry weight with insurance companies. Most private insurance plans are required to cover all recommended testing options, including follow-up testing, without copays, starting with plan years beginning in 2027.
The expansion of HPV screening with self-collection has the potential to dramatically broaden access to preventative care. Individuals could potentially be screened at primary care offices, urgent care clinics, mobile health units, or even pharmacies, or choose to collect samples at home. This is particularly beneficial for those who lack access to a gynecologist or feel uncomfortable with traditional pelvic exams.
the most important message is that regular cervical cancer screening is crucial for everyone with a cervix. Anyone with questions about their individual screening needs or which test is best suited for them should consult with a healthcare provider.
Disclaimer: This article provides general information about medical guidelines and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized guidance and treatment.
The implementation of these updated guidelines will continue to unfold in the coming months and years. The next key step will be observing how quickly healthcare providers adopt HPV primary testing and integrate self-collection options into their practices. We will continue to follow these developments and provide updates as they become available.
Have thoughts on these new guidelines? Share your comments and questions below.
